Top 5 consolidation, cutback & closure articles of 2010

By Nick Taylor

- Last updated on GMT

Related tags: Early stage, Mds pharma services, Supply and demand

The contract service market failed to recover as hoped in 2010 and consequently many companies made cutbacks. Outsourcing-Pharma rounds up five of the most read of 2010.

What’s the deal with Azopharma?

In April Azopharma quietly closed its doors. As news of the development began to emerge Outsourcing-Pharma wrote a brief article to cover what was known so far. Since then more details have come to light, Azopharma equipment has been auctioned​ and research animals rehomed​.

Charles River and Covance post Q3 losses and announce job cuts

In third quarter results both Covance and Charles River Laboratories (CRL) revealed plans to close facilities in Quebec and Virginia, leading to lay offs of 200 and 300 staff respectively. Both companies planned to move operations to other sites in response to lower demand.

CRL to halt preclinical ops in Shrewsbury on low demand

CRL began and ended the year by proposing site exits, continuing the cost-cutting it began in 2009. In January the company said it was stopping preclinical operations at a site in Massachusetts, US, at a cost of 300 jobs, because of low demand.

Earlier this month CRL proposed the sale​ of a US Phase I site and a preclinical unit in China. Some investors would like to see CRL go even further and consider selling or splitting the business.

MDS finds buyers for Pharma Services; 275 jobs will be lost

The fate of remaining MDS Pharma Services’ units was confirmed when Ricerca Biosciences bought preclinical and discovery sites and private investors acquired early stage facilities.

However, MDS Montreal, Canada site was excluded from either deal and closed. This, coupled to redundancies at early stage sites, led to 225 job losses. A further 50 employees, mainly from finance, IT and human resources, also lost their jobs and MDS headquarters closed.

Kendle’s operating income falls; cutting jobs in Q1

Kendle outlined plans to cut jobs in February after delays and cancellations impacted on financials. Furthermore, Kendle was concerned about “continued volatility​” in the market and in response initiated cuts expected to save $18m (€14m) in 2010.

It is feasible Kendle could begin 2011 with plans for further cutbacks. In its fourth quarter conference call, due in February 2011, Kendle will discuss findings of its early stage review. This will establish fair value and consider all options, from complete exit to refocusing.

Related news

Related products

show more

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 15-Jul-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

Empowering Clinical Trial Sponsors with Analytics

Empowering Clinical Trial Sponsors with Analytics

PerkinElmer | 14-Jul-2021 | Technical / White Paper

Is your Clinical Data Review creating problems or solving them? Take Control of Your Data. PerkinElmer Informatics Clinical Solutions, powered by Tibco...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

Related suppliers

Follow us

Products

View more

Webinars